 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- MT1980 / Monument Therap
TARGETING NEUROINFLAMMATION IN NEURODEGENERATIVE DISORDERS: A FIRST IN HUMAN STUDY OF MT1980, A NOVEL FORMULATED ANTI-INFLAMMATORY MEDICINE (ONSITE - HALL G3) - Dec 23, 2022 - Abstract #ADPD2023ADPD_965;
Concentrations of drug achieved in the CSF were at levels anticipated to provide meaningful anti-inflammatory effects, suggesting MT1980 has potential utility as a novel treatment of neuroinflammatory conditions. A further clinical study to assess PK and anti-neuroinflammatory effects is now planned.
- || MT1980 / Monument Therap
Trial completion: Safety & PK of Single Doses of MT1980 (clinicaltrials.gov) - Nov 2, 2022
P1, N=24, Completed, Sponsor: Monument Therapeutics Limited
A further clinical study to assess PK and anti-neuroinflammatory effects is now planned. Active, not recruiting --> Completed
- || MT1980 / Monument Therap
Enrollment closed: Safety & PK of Single Doses of MT1980 (clinicaltrials.gov) - Sep 27, 2022
P1, N=24, Active, not recruiting, Sponsor: Monument Therapeutics Limited
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || MT1980 / Monument Therap
New P1 trial: Safety & PK of Single Doses of MT1980 (clinicaltrials.gov) - Jun 22, 2022
P1, N=32, Recruiting, Sponsor: Monument Therapeutics Limited